Brief: Histogen Announces Completion Of Final Dosing Timepoint Milestone In Its 1B/2A Trial For Androgenic Alopecia In Men
05/10/2020 13:35
Oct 5 (Reuters) - Histogen Inc HSTO.O :
* HISTOGEN ANNOUNCES COMPLETION OF FINAL DOSING TIMEPOINT
MILESTONE IN ITS 1B/2A TRIAL FOR ANDROGENIC ALOPECIA IN MEN
Source text for Eikon: ID:nGNX5QpX7C
Further company coverage: HSTO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up